Infection and immune control of human oncogenic γ-herpesviruses in humanized mice.
Epstein–Barr virus
Kaposi sarcoma-associated herpesvirus
anti-viral immune control
humanized mice
lymphoma
Journal
Philosophical transactions of the Royal Society of London. Series B, Biological sciences
ISSN: 1471-2970
Titre abrégé: Philos Trans R Soc Lond B Biol Sci
Pays: England
ID NLM: 7503623
Informations de publication
Date de publication:
27 05 2019
27 05 2019
Historique:
entrez:
9
4
2019
pubmed:
9
4
2019
medline:
24
3
2020
Statut:
ppublish
Résumé
Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) comprise the oncogenic human γ-herpesvirus family and are responsible for 2-3% of all tumours in man. With their prominent growth-transforming abilities and high prevalence in the human population, these pathogens have probably shaped the human immune system throughout evolution for near perfect immune control of the respective chronic infections in the vast majority of healthy pathogen carriers. The exclusive tropism of EBV and KSHV for humans has, however, made it difficult in the past to study their infection, tumourigenesis and immune control in vivo. Mice with reconstituted human immune system components (humanized mice) support replication of both viruses with both persisting latent and productive lytic infection. Moreover, B-cell lymphomas can be induced by EBV alone and KSHV co-infection with gene expression hallmarks of human malignancies that are associated with both viruses. Furthermore, cell-mediated immune control by primarily cytotoxic lymphocytes is induced upon infection and can be probed for its functional characteristics as well as putative requirements for its priming. Insights that have been gained from this model and remaining questions will be discussed in this review. This article is part of the theme issue 'Silent cancer agents: multi-disciplinary modelling of human DNA oncoviruses'.
Identifiants
pubmed: 30955487
doi: 10.1098/rstb.2018.0296
pmc: PMC6501906
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
20180296Références
J Immunol. 2005 Oct 1;175(7):4355-62
pubmed: 16177076
Lancet. 1995 Sep 23;346(8978):799-802
pubmed: 7674745
Immunity. 2000 Oct;13(4):497-506
pubmed: 11070168
Blood. 2005 Sep 15;106(6):2091-8
pubmed: 15947093
J Clin Invest. 2016 Oct 3;126(10):3772-3782
pubmed: 27571408
PLoS Pathog. 2018 Aug 20;14(8):e1007221
pubmed: 30125329
Blood. 2008 Oct 15;112(8):3293-302
pubmed: 18635810
PLoS Pathog. 2015 Dec 01;11(12):e1005286
pubmed: 26624012
Immunity. 1998 Sep;9(3):395-404
pubmed: 9768759
Cancer Immunol Res. 2014 Jan;2(1):9-14
pubmed: 24778160
J Virol. 2011 Jul;85(14):7321-32
pubmed: 21543487
PLoS Pathog. 2014 Aug 28;10(8):e1004333
pubmed: 25165855
Annu Rev Pathol. 2014;9:349-72
pubmed: 24111911
Annu Rev Immunol. 2011;29:665-705
pubmed: 21219180
Cancer Res. 2009 Oct 15;69(20):7935-44
pubmed: 19808969
J Infect Dis. 2013 Jan 1;207(1):80-8
pubmed: 23100562
PLoS Pathog. 2018 Mar 22;14(3):e1006933
pubmed: 29566098
J Virol. 2003 Feb;77(3):1840-7
pubmed: 12525618
Virology. 2002 Dec 20;304(2):342-51
pubmed: 12504574
Blood. 2008 Aug 15;112(4):1231-9
pubmed: 18519810
J Virol. 2011 Jan;85(1):165-77
pubmed: 20980506
J Immunol. 2014 May 15;192(10):4492-6
pubmed: 24740502
Curr Top Microbiol Immunol. 2015;391:119-49
pubmed: 26428373
J Exp Med. 2009 Jun 8;206(6):1423-34
pubmed: 19487422
Nat Rev Immunol. 2016 Feb;16(2):79-89
pubmed: 26688350
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1656-61
pubmed: 18230726
Blood. 2003 May 15;101(10):4115-21
pubmed: 12531789
J Exp Med. 2002 Apr 1;195(7):893-905
pubmed: 11927633
Cell Host Microbe. 2017 Jul 12;22(1):61-73.e7
pubmed: 28704654
PLoS Pathog. 2018 Apr 30;14(4):e1007039
pubmed: 29709016
Cell Rep. 2013 Oct 31;5(2):458-70
pubmed: 24120866
PLoS Pathog. 2016 May 17;12(5):e1005642
pubmed: 27186886
Blood. 2001 Feb 15;97(4):835-43
pubmed: 11159505
J Virol. 2014 Mar;88(6):3235-45
pubmed: 24390326
J Clin Invest. 2001 Jan;107(1):121-30
pubmed: 11134187
J Virol. 2005 Nov;79(22):13993-4003
pubmed: 16254335
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
Annu Rev Pathol. 2006;1:273-96
pubmed: 18039116
J Clin Invest. 2012 Apr;122(4):1487-502
pubmed: 22406538
J Clin Invest. 2017 Jun 1;127(6):2066-2080
pubmed: 28504647
J Immunol. 2002 Aug 1;169(3):1593-603
pubmed: 12133989
Curr Opin Virol. 2016 Oct;20:71-77
pubmed: 27665065
Curr Opin Virol. 2015 Oct;14:79-86
pubmed: 26372881
J Exp Med. 2003 Sep 15;198(6):903-11
pubmed: 12975456
Cancer Cell. 2014 Oct 13;26(4):565-76
pubmed: 25220446
Hematol Oncol. 2018 Feb;36(1):316-319
pubmed: 28580733
J Virol. 2007 Jan;81(2):474-82
pubmed: 17079298
J Infect Dis. 2015 Sep 1;212(5):803-7
pubmed: 25722295
Annu Rev Pathol. 2017 Jan 24;12:187-215
pubmed: 27959627
J Virol. 2000 Jun;74(11):5300-9
pubmed: 10799607
J Clin Invest. 2005 Sep;115(9):2546-55
pubmed: 16110323
J Virol. 2005 Jan;79(2):1296-307
pubmed: 15613356
J Exp Med. 2017 Feb;214(2):269-283
pubmed: 28108590
Blood. 2013 Oct 10;122(15):2600-8
pubmed: 23974196
Immunity. 2000 Sep;13(3):365-74
pubmed: 11021534
Viruses. 2014 Oct 23;6(10):4047-79
pubmed: 25341666
Oncotarget. 2017 Feb 7;8(6):10238-10254
pubmed: 28052012
J Virol. 2012 Aug;86(15):7976-87
pubmed: 22623780
PLoS Pathog. 2012 Sep;8(9):e1002902
pubmed: 22969425
Viruses. 2014 Nov 24;6(11):4731-59
pubmed: 25421895
J Exp Med. 2006 Apr 17;203(4):805-8
pubmed: 16549599
J Exp Med. 2017 Jun 5;214(6):1827-1841
pubmed: 28468758
J Virol. 2003 Jun;77(11):6546-50
pubmed: 12743312
Sci Transl Med. 2011 Nov 2;3(107):107fs7
pubmed: 22049067
N Engl J Med. 2004 Mar 25;350(13):1328-37
pubmed: 15044644
Curr Opin Virol. 2017 Aug;25:113-118
pubmed: 28837889
J Virol. 2007 Jun;81(11):6068-78
pubmed: 17376914
Nat Med. 2002 Apr;8(4):379-85
pubmed: 11927944
Blood. 1997 Dec 15;90(12):4894-900
pubmed: 9389706
Curr Top Microbiol Immunol. 2015;391:61-117
pubmed: 26428372
Nat Rev Cancer. 2016 Dec;16(12):789-802
pubmed: 27687982
Cell Rep. 2013 Dec 26;5(6):1489-98
pubmed: 24360958
Am J Pathol. 2008 Nov;173(5):1369-78
pubmed: 18845836
J Virol. 2005 Apr;79(7):4506-9
pubmed: 15767450
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8
pubmed: 9928727
J Virol. 2017 Jul 27;91(16):
pubmed: 28592533
J Virol. 2017 Mar 13;91(7):
pubmed: 28077657
Curr Top Microbiol Immunol. 2015;391:427-54
pubmed: 26428384
Blood. 2013 Feb 28;121(9):1584-94
pubmed: 23297134
J Infect Dis. 1997 Jul;176(1):94-102
pubmed: 9207354
Br J Haematol. 2005 Apr;129(2):266-74
pubmed: 15813855
Curr Top Microbiol Immunol. 2015;391:355-81
pubmed: 26428381
Blood Adv. 2017 Dec 14;1(27):2679-2691
pubmed: 29296921
N Engl J Med. 1976 Jun 17;294(25):1355-9
pubmed: 177872
Adv Immunol. 2015;127:145-201
pubmed: 26073984
N Engl J Med. 1999 Apr 8;340(14):1063-70
pubmed: 10194235
Int J Cancer. 2006 Jun 15;118(12):3030-44
pubmed: 16404738
Cell Host Microbe. 2010 Dec 16;8(6):510-22
pubmed: 21147465
J Virol. 2013 Sep;87(17):9398-410
pubmed: 23785197
J Infect Dis. 2009 Nov 15;200(10):1611-5
pubmed: 19832115
PLoS Pathog. 2012 Sep;8(9):e1002889
pubmed: 23028307
Curr Top Microbiol Immunol. 2015;390(Pt 1):241-65
pubmed: 26424649
Annu Rev Med. 2005;56:29-44
pubmed: 15660500
Nat Med. 2002 Jun;8(6):594-9
pubmed: 12042810
J Immunol. 2001 Aug 15;167(4):2019-29
pubmed: 11489984
Nat Med. 2003 Mar;9(3):307-14
pubmed: 12592401
Blood. 2014 Oct 16;124(16):2533-43
pubmed: 25205117
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3146-51
pubmed: 24516154
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404
pubmed: 12925741
J Virol. 2003 Nov;77(22):12088-104
pubmed: 14581546
Blood. 2013 Jun 20;121(25):5034-44
pubmed: 23482932
J Infect Dis. 1998 Jan;177(1):213-6
pubmed: 9419191
J Clin Invest. 2015 Jan;125(1):304-15
pubmed: 25485679
Scand J Immunol. 2007 Aug-Sep;66(2-3):335-44
pubmed: 17635811
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679955
Blood. 2014 Jan 16;123(3):346-55
pubmed: 24196073
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893942
Cell Host Microbe. 2009 Apr 23;5(4):376-85
pubmed: 19380116
PLoS Pathog. 2016 Aug 19;12(8):e1005799
pubmed: 27540722